{"protocolSection": {"identificationModule": {"nctId": "NCT02956044", "orgStudyIdInfo": {"id": "THR-1442-C-453"}, "organization": {"fullName": "Theracos", "class": "INDUSTRY"}, "briefTitle": "Interaction of Bexagliflozin With Metformin, Glimepiride and Sitagliptin", "officialTitle": "A Phase 1, Open-label, Randomized, Three-period, Crossover Study to Evaluate Pharmacokinetic Interaction Between Bexagliflozin Tablets and Metformin, Glimepiride, or Sitagliptin in Healthy Subjects"}, "statusModule": {"statusVerifiedDate": "2021-07", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2016-11"}, "primaryCompletionDateStruct": {"date": "2017-03", "type": "ACTUAL"}, "completionDateStruct": {"date": "2017-03", "type": "ACTUAL"}, "studyFirstSubmitDate": "2016-11-02", "studyFirstSubmitQcDate": "2016-11-02", "studyFirstPostDateStruct": {"date": "2016-11-04", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2021-05-21", "resultsFirstSubmitQcDate": "2021-07-01", "resultsFirstPostDateStruct": {"date": "2021-07-22", "type": "ACTUAL"}, "lastUpdateSubmitDate": "2021-07-01", "lastUpdatePostDateStruct": {"date": "2021-07-22", "type": "ACTUAL"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "Theracos", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true, "isFdaRegulatedDrug": true, "isFdaRegulatedDevice": false}, "descriptionModule": {"briefSummary": "The purpose of this study is to examine the drug-drug interaction in your body when given the study drug, bexagliflozin, with three commonly used ant-diabetic medications, metformin, glimepiride or sitagliptin. The study will also evaluate how safe the study drug is and how well the study drug is tolerated when taken with metformin, glimepiride or sitagliptin.", "detailedDescription": "A total of 54 healthy subjects were enrolled and assigned to one of three groups of eighteen. Each group participated in one of three open-label, randomized, three treatment period, crossover studies:\n\n* Group 1: Bexagliflozin/metformin drug-drug interaction (DDI)\n* Group 2: Bexagliflozin/glimepiride DDI\n* Group 3: Bexagliflozin/sitagliptin DDI For each Group, every subject received a single dose of bexagliflozin tablet, 20 mg, alone, a single dose of an oral hypoglycemic agent (OHA) (1000 mg metformin, 2 mg glimepiride, or 100 mg sitagliptin) alone, and the combination of both (bexagliflozin tablet and OHA) alternately in a crossover fashion, with three treatment periods separated by a washout period of at least 7 days. Within each Group, subjects were randomized to one of six treatment sequences in an equal ratio.\n\nTo prevent hypoglycemia, subjects assigned to Group 2 (bexagliflozin/glimepiride DDI) received approximately 300 mL of a solution containing 50 g of glucose with study medication at the time of dosing, as well as approximately 75 mL of a solution containing 12.5 g of glucose every 15 minutes for 4 hours post-dose.\n\nFor each treatment period in Group 1 (bexagliflozin/metformin DDI) and Group 2 (bexagliflozin/glimepiride DDI), subjects were admitted to the clinic on the day before dosing and stayed in the clinic until 48 h post-dose. For Group 3 (bexagliflozin/sitagliptin DDI), subjects stayed in the clinic until 72 h post-dose.\n\nFor all Groups, blood samples for PK analysis were collected in each period prior to dosing (pre-dose) and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose. For Group 3, PK blood samples were also collected at 60 and 72 h post-dose. Plasma concentrations of bexagliflozin and OHAs were determined by validated liquid chromatography tandem mass spectrometry (LC MS/MS) assays.\n\nUrine samples for PD analysis were collected in 12 h intervals. For all Groups, urine samples were collected pre-dose (-12 to 0 h) and post-dose at 0 to 12 h, 12 to 24 h, 24 to 36 h, and 36 to 48 h. For Group 3, additional samples at 48 to 60 h and 60 to 72 h post-dose were collected."}, "conditionsModule": {"conditions": ["Type2 Diabetes Mellitus"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE1"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "CROSSOVER", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "NONE"}}, "enrollmentInfo": {"count": 54, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Group 1: Bexagliflozin alone", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Bexagliflozin"]}, {"label": "Group 1: Metformin alone", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Metformin"]}, {"label": "Group 1: Bexagliflozin + Metformin", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Bexagliflozin", "Drug: Metformin"]}, {"label": "Group 2: Bexagliflozin alone", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Bexagliflozin"]}, {"label": "Group 2: Glimepiride alone", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Glimepiride"]}, {"label": "Group 2: Bexagliflozin + Glimepiride", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Bexagliflozin", "Drug: Glimepiride"]}, {"label": "Group 3: Bexagliflozin alone", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Bexagliflozin"]}, {"label": "Group 3: Sitagliptin alone", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Sitagliptin"]}, {"label": "Group 3: Bexagliflozin + Sitagliptin", "type": "ACTIVE_COMPARATOR", "interventionNames": ["Drug: Bexagliflozin", "Drug: Sitagliptin"]}], "interventions": [{"type": "DRUG", "name": "Bexagliflozin", "description": "Bexagliflozin tablets, 20 mg", "armGroupLabels": ["Group 1: Bexagliflozin + Metformin", "Group 1: Bexagliflozin alone", "Group 2: Bexagliflozin + Glimepiride", "Group 2: Bexagliflozin alone", "Group 3: Bexagliflozin + Sitagliptin", "Group 3: Bexagliflozin alone"]}, {"type": "DRUG", "name": "Metformin", "description": "1000 mg metformin", "armGroupLabels": ["Group 1: Bexagliflozin + Metformin", "Group 1: Metformin alone"]}, {"type": "DRUG", "name": "Glimepiride", "description": "4 mg glimepiride", "armGroupLabels": ["Group 2: Bexagliflozin + Glimepiride", "Group 2: Glimepiride alone"]}, {"type": "DRUG", "name": "Sitagliptin", "description": "100 mg sitagliptin", "armGroupLabels": ["Group 3: Bexagliflozin + Sitagliptin", "Group 3: Sitagliptin alone"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Cmax (Maximum Observed Plasma Concentration)", "description": "Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations.", "timeFrame": "Up to 72 hours"}, {"measure": "Tmax (Time of Maximum Observed Plasma Concentration)", "description": "Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations.", "timeFrame": "Up to 72 hours"}, {"measure": "T1/2 (Apparent Terminal Elimination Half-life)", "description": "Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations.", "timeFrame": "Up to 72 hours"}, {"measure": "AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)", "description": "Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject.", "timeFrame": "Up to 72 hours"}], "secondaryOutcomes": [{"measure": "Urinary Glucose Excretion up to 0-72 hr", "description": "Pre-dose urine samples were collected from -12 to 0 h for baseline measurement. Subjects was instructed to empty their bladder prior to dosing. Post-dose urine was collected in 4 batches for Groups 1 and 2 at 0 to 12 h, 12 to 24 h, 24 o 36 h, and 36 to 48 h collections. Post-dose urine was collected in batches for Group 3 at 0 to 12 h, 12 to 24 h, 24 to 36 h, 36 to 48 h, 48 to 60 h and 60 to 72 h.", "timeFrame": "up to 0-72 hr"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n1. Subjects with body-mass index (BMI) between 18.0 kg/m2 and 32.0 kg/m2\n2. Subjects who are non-smokers for at least 3 months prior to screening\n3. Subjects who are willing and able to be confined to the clinical research facility as required by the protocol\n\nExclusion Criteria:\n\n1. Subjects with a clinically significant history of allergy to drugs or latex.\n2. Subjects with a history of alcohol or drug dependence in the past 12 months.\n3. Subjects who have donated a significant amount of blood in the past 2 months\n4. Female subjects who are pregnant or breastfeeding\n5. Subjects who are not willing to use an adequate form of birth control during the study and for 30 days after discharge from clinic\n6. Subjects who have taken an investigational drug in the past 30 days or 7 half-lives of the investigational drug, whichever is longer\n7. Subjects who had previously received anti-diabetic medication, including metformin, sitagliptin, glimepiride or drugs of the same class (i.e. biguanides, DPP-4 inhibitors or sulfonylureas), or SGLT2 inhibitors, in the past 3 months", "healthyVolunteers": true, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "65 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Mason Freeman, M.D.", "affiliation": "Massachusetts General Hospital", "role": "STUDY_CHAIR"}], "locations": [{"facility": "Clinical Research Site", "city": "Evansville", "state": "Indiana", "zip": "47710", "country": "United States", "geoPoint": {"lat": 37.97476, "lon": -87.55585}}]}, "ipdSharingStatementModule": {"ipdSharing": "NO"}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Group 1: Bexagliflozin + Metformin", "description": "Bexagliflozin tablets 20 mg alone, Metformin tablets 1000 mg alone, or Bexagliflozin 20 mg + Metformin 1000 mg"}, {"id": "FG001", "title": "Group 2: Bexagliflozin + Glimepiride", "description": "Bexagliflozin tablets 20 mg alone, Glimepiride tablets 2 mg alone, or Bexagliflozin 20 mg + Glimepiride 2 mg"}, {"id": "FG002", "title": "Group 3: Bexagliflozin + Sitagliptin", "description": "Bexagliflozin tablets 20 mg alone, Sitagliptin 100 mg alone, or Bexagliflozin 20 mg + Sitagliptin 100 mg"}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "18"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "18"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "0"}, {"groupId": "FG002", "numSubjects": "0"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Group 1: Bexagliflozin + Metformin", "description": "Bexagliflozin tablets 20 mg alone, Metformin tablets 1000 mg alone, or Bexagliflozin 20 mg + Metformin 1000 mg"}, {"id": "BG001", "title": "Group 2: Bexagliflozin + Glimepiride", "description": "Bexagliflozin tablets 20 mg alone, Glimepiride tablets 2 mg alone, or Bexagliflozin 20 mg + Glimepiride 2 mg"}, {"id": "BG002", "title": "Group 3: Bexagliflozin + Sitagliptin", "description": "Bexagliflozin tablets 20 mg alone, Sitagliptin 100 mg alone, or Bexagliflozin 20 mg + Sitagliptin 100 mg"}, {"id": "BG003", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "18"}, {"groupId": "BG003", "value": "54"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "42.2", "spread": "15.69"}, {"groupId": "BG001", "value": "37.6", "spread": "8.25"}, {"groupId": "BG002", "value": "43.6", "spread": "14.52"}, {"groupId": "BG003", "value": "41.1", "spread": "13.2"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "6"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "20"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "12"}, {"groupId": "BG001", "value": "13"}, {"groupId": "BG002", "value": "9"}, {"groupId": "BG003", "value": "34"}]}]}]}, {"title": "Ethnicity (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "1"}, {"groupId": "BG003", "value": "1"}]}, {"title": "Not Hispanic or Latino", "measurements": [{"groupId": "BG000", "value": "18"}, {"groupId": "BG001", "value": "18"}, {"groupId": "BG002", "value": "17"}, {"groupId": "BG003", "value": "53"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}]}]}, {"title": "Race (NIH/OMB)", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "American Indian or Alaska Native", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Asian", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Native Hawaiian or Other Pacific Islander", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Black or African American", "measurements": [{"groupId": "BG000", "value": "5"}, {"groupId": "BG001", "value": "5"}, {"groupId": "BG002", "value": "10"}, {"groupId": "BG003", "value": "20"}]}, {"title": "White", "measurements": [{"groupId": "BG000", "value": "13"}, {"groupId": "BG001", "value": "12"}, {"groupId": "BG002", "value": "8"}, {"groupId": "BG003", "value": "33"}]}, {"title": "More than one race", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "0"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "0"}]}, {"title": "Unknown or Not Reported", "measurements": [{"groupId": "BG000", "value": "0"}, {"groupId": "BG001", "value": "1"}, {"groupId": "BG002", "value": "0"}, {"groupId": "BG003", "value": "1"}]}]}]}, {"title": "Weight", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "kg", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "79.0", "spread": "11.75"}, {"groupId": "BG001", "value": "77.9", "spread": "12.37"}, {"groupId": "BG002", "value": "79.0", "spread": "13.21"}, {"groupId": "BG003", "value": "78.6", "spread": "12.23"}]}]}]}, {"title": "Height", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "cm", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "173.3", "spread": "9.16"}, {"groupId": "BG001", "value": "172.3", "spread": "6.45"}, {"groupId": "BG002", "value": "170.5", "spread": "8.37"}, {"groupId": "BG003", "value": "172.0", "spread": "8.01"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Cmax (Maximum Observed Plasma Concentration)", "description": "Whole venous blood samples of 5 mL were be collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. Pharmacokinetic (PK) blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Cmax was obtained directly from experimental observations.", "populationDescription": "The study was designed to evaluate the potential bexagliflozin drug interactions. Study participants were dosed with bexagliflozin alone, other drug alone or both drugs sequentially. The pharmacokinetic parameters were calculated based on the specific analyte using samples collected after dosing of the drug. Therefore, not all samples were analyzed for all outcome measurements.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "ng/mL", "timeFrame": "Up to 72 hours", "groups": [{"id": "OG000", "title": "Group 1: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG001", "title": "Group 1: Metformin Alone", "description": "Metformin: Metformin tablets, 1000 mg"}, {"id": "OG002", "title": "Group 1: Bexagliflozin + Metformin", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nMetformin: Metformin tablets, 1000 mg"}, {"id": "OG003", "title": "Group 2: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG004", "title": "Group 2: Glimepiride Alone", "description": "Glimepiride: Glimepiride tablets, 2 mg"}, {"id": "OG005", "title": "Group 2: Bexagliflozin + Glimepiride", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nGlimepiride: Glimepiride tablets, 2 mg"}, {"id": "OG006", "title": "Group 3: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG007", "title": "Group 3: Sitagliptin Alone", "description": "Sitagliptin: Sitagliptin tablets, 100 mg"}, {"id": "OG008", "title": "Group 3: Bexagliflozin + Sitagliptin", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nSitagliptin: Sitagliptin tablets, 100 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "17"}, {"groupId": "OG004", "value": "18"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "18"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "18"}]}], "classes": [{"title": "Bexagliflozin PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "17"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "18"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "124.6", "spread": "43.7"}, {"groupId": "OG002", "value": "135.5", "spread": "40.0"}, {"groupId": "OG003", "value": "158.6", "spread": "53.9"}, {"groupId": "OG005", "value": "143.7", "spread": "37.9"}, {"groupId": "OG006", "value": "117.1", "spread": "34.6"}, {"groupId": "OG008", "value": "148.3", "spread": "22.1"}]}]}, {"title": "Metformin PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "2067.6", "spread": "27.2"}, {"groupId": "OG002", "value": "1965.2", "spread": "33.6"}]}]}, {"title": "Glimepiride PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "18"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG004", "value": "59.9", "spread": "32.2"}, {"groupId": "OG005", "value": "67.1", "spread": "29.5"}]}]}, {"title": "Sitagliptin PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG007", "value": "356.6", "spread": "22.3"}, {"groupId": "OG008", "value": "351.2", "spread": "32.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Geometric Least Square (LS) Mean was used as PK parameters", "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "The acceptance range for bioequivalence is 80.0 - 125.00%", "paramType": "Ratio of Geometric LSM", "paramValue": "108.73", "ciPctValue": "95", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "94.35", "ciUpperLimit": "125.30", "estimateComment": "Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Geometric LS Mean was used as PK parameters", "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "The acceptance range for bioequivalence is 80.0 - 125.00%", "paramType": "Ratio of Geometric LSM", "paramValue": "95.05", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "84.73", "ciUpperLimit": "106.63", "estimateComment": "Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect"}, {"groupIds": ["OG003", "OG005"], "groupDescription": "Geometric LS Mean was used as PK parameters", "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "The acceptance range for bioequivalence is 80.0 - 125.00%", "paramType": "Ratio of Geometric LSM", "paramValue": "89.44", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "70.39", "ciUpperLimit": "113.65", "estimateComment": "Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect"}, {"groupIds": ["OG004", "OG005"], "groupDescription": "Geometric LS Mean was used as PK parameters", "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "The acceptance range for bioequivalence is 80.0 - 125.00%", "paramType": "Ratio of Geometric LSM", "paramValue": "111.95", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "97.02", "ciUpperLimit": "129.19", "estimateComment": "Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect"}, {"groupIds": ["OG006", "OG008"], "groupDescription": "Geometric LS Mean was used as PK parameters", "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "The acceptance range for bioequivalence is 80.0 - 125.00%", "paramType": "Ratio of Geometric LSM", "paramValue": "126.68", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "112.08", "ciUpperLimit": "143.17", "estimateComment": "Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect"}, {"groupIds": ["OG007", "OG008"], "groupDescription": "Geometric LS Mean was used as PK parameters", "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "The acceptance range for bioequivalence is 80.0 - 125.00%", "paramType": "Ratio of Geometric LSM", "paramValue": "98.48", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "84.90", "ciUpperLimit": "114.23", "estimateComment": "Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect"}]}, {"type": "PRIMARY", "title": "Tmax (Time of Maximum Observed Plasma Concentration)", "description": "Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. Tmax was obtained directly from experimental observations.", "populationDescription": "The study was designed to evaluate the potential bexagliflozin drug interactions. Study participants were dosed with bexagliflozin alone, other drug alone or both drugs sequentially. The pharmacokinetic parameters were calculated based on the specific analyte using samples collected after dosing of the drug. Therefore, not all samples were analyzed for all outcome measurements.", "reportingStatus": "POSTED", "paramType": "MEDIAN", "dispersionType": "Full Range", "unitOfMeasure": "hours", "timeFrame": "Up to 72 hours", "groups": [{"id": "OG000", "title": "Group 1: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG001", "title": "Group 1: Metformin Alone", "description": "Metformin: Metformin tablets, 1000 mg"}, {"id": "OG002", "title": "Group 1: Bexagliflozin + Metformin", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nMetformin: Metformin tablets, 1000 mg"}, {"id": "OG003", "title": "Group 2: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG004", "title": "Group 2: Glimepiride Alone", "description": "Glimepiride: Glimepiride tablets, 2 mg"}, {"id": "OG005", "title": "Group 2: Bexagliflozin + Glimepiride", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nGlimepiride: Glimepiride tablets, 2 mg"}, {"id": "OG006", "title": "Group 3: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG007", "title": "Group 3: Sitagliptin Alone", "description": "Sitagliptin: Sitagliptin tablets, 100 mg"}, {"id": "OG008", "title": "Group 3: Bexagliflozin + Sitagliptin", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nSitagliptin: Sitagliptin tablets, 100 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "17"}, {"groupId": "OG004", "value": "18"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "18"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "18"}]}], "classes": [{"title": "Bexagliflozin PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "17"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "18"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "4.0", "lowerLimit": "1", "upperLimit": "5"}, {"groupId": "OG002", "value": "3.0", "lowerLimit": "1", "upperLimit": "5"}, {"groupId": "OG003", "value": "8.0", "lowerLimit": "5", "upperLimit": "10"}, {"groupId": "OG005", "value": "6.0", "lowerLimit": "5", "upperLimit": "10"}, {"groupId": "OG006", "value": "3.0", "lowerLimit": "2", "upperLimit": "5"}, {"groupId": "OG008", "value": "4.0", "lowerLimit": "2", "upperLimit": "5"}]}]}, {"title": "Metformin PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "18"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "2.5", "lowerLimit": "1", "upperLimit": "3"}, {"groupId": "OG002", "value": "2.0", "lowerLimit": "1", "upperLimit": "5"}, {"groupId": "OG004", "value": "0", "lowerLimit": "0", "upperLimit": "0"}]}]}, {"title": "Glimepiride PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "18"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG004", "value": "5.5", "lowerLimit": "1", "upperLimit": "10"}, {"groupId": "OG005", "value": "7.0", "lowerLimit": "1", "upperLimit": "10"}]}]}, {"title": "Sitagliptin PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG007", "value": "2.5", "lowerLimit": "1", "upperLimit": "5"}, {"groupId": "OG008", "value": "2.5", "lowerLimit": "1", "upperLimit": "6"}]}]}]}, {"type": "PRIMARY", "title": "T1/2 (Apparent Terminal Elimination Half-life)", "description": "Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. T1/2 was obtained directly from experimental observations.", "populationDescription": "The study was designed to evaluate the potential bexagliflozin drug interactions. Study participants were dosed with bexagliflozin alone, other drug alone or both drugs sequentially. The pharmacokinetic parameters were calculated based on the specific analyte using samples collected after dosing of the drug. Therefore, not all samples were analyzed for all outcome measurements.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "hours", "timeFrame": "Up to 72 hours", "groups": [{"id": "OG000", "title": "Group 1: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG001", "title": "Group 1: Metformin Alone", "description": "Metformin: Metformin tablets, 1000 mg"}, {"id": "OG002", "title": "Group 1: Bexagliflozin + Metformin", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nMetformin: Metformin tablets, 1000 mg"}, {"id": "OG003", "title": "Group 2: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG004", "title": "Group 2: Glimepiride Alone", "description": "Glimepiride: Glimepiride tablets, 4 mg"}, {"id": "OG005", "title": "Group 2: Bexagliflozin + Glimepiride", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nGlimepiride: Glimepiride tablets, 4 mg"}, {"id": "OG006", "title": "Group 3: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG007", "title": "Group 3: Sitagliptin Alone", "description": "Sitagliptin: Sitagliptin tablets, 100 mg"}, {"id": "OG008", "title": "Group 3: Bexagliflozin + Sitagliptin", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nSitagliptin: Sitagliptin tablets, 100 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "17"}, {"groupId": "OG004", "value": "18"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "17"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "18"}]}], "classes": [{"title": "Bexagliflozin PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "17"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "17"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "10.3", "spread": "30.4"}, {"groupId": "OG002", "value": "7.8", "spread": "48.6"}, {"groupId": "OG003", "value": "8.0", "spread": "33.3"}, {"groupId": "OG005", "value": "7.8", "spread": "34.4"}, {"groupId": "OG006", "value": "12.6", "spread": "48"}, {"groupId": "OG008", "value": "13.3", "spread": "38.2"}]}]}, {"title": "Metformin PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "9.0", "spread": "31.8"}, {"groupId": "OG002", "value": "10.2", "spread": "32.5"}]}]}, {"title": "Glimepiride PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "18"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG004", "value": "7.8", "spread": "46.8"}, {"groupId": "OG005", "value": "6.6", "spread": "57.8"}]}]}, {"title": "Sitagliptin PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG007", "value": "14.3", "spread": "22.3"}, {"groupId": "OG008", "value": "14.8", "spread": "24.5"}]}]}]}, {"type": "PRIMARY", "title": "AUC0-inf (Area Under the Plasma Concentration-time Curve From Time 0 to Infinity)", "description": "Whole venous blood samples of 5 mL were collected from a peripheral vein in each period at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, and 48 h post-dose for Group 1 and 2. PK blood samples were collected at pre-dose and at 0.5, 1, 2, 3, 4, 5, 6, 8, 10, 12, 16, 24, 36, 48, 60 and 72 h post-dose for Group 3. Plasma was obtained from centrifugation, frozen and analyzed. AUC0-inf was estimated for each subject.", "populationDescription": "The study was designed to evaluate the potential bexagliflozin drug interactions. Study participants were dosed with bexagliflozin alone, other drug alone or both drugs sequentially. The pharmacokinetic parameters were calculated based on the specific analyte using samples collected after dosing of the drug. Therefore, not all samples were analyzed for all outcome measurements.", "reportingStatus": "POSTED", "paramType": "GEOMETRIC_MEAN", "dispersionType": "Geometric Coefficient of Variation", "unitOfMeasure": "h*ng/mL", "timeFrame": "Up to 72 hours", "groups": [{"id": "OG000", "title": "Group 1: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG001", "title": "Group 1: Metformin Alone", "description": "Metformin: Metformin tablets, 1000 mg"}, {"id": "OG002", "title": "Group 1: Bexagliflozin + Metformin", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nMetformin: Metformin tablets, 1000 mg"}, {"id": "OG003", "title": "Group 2: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG004", "title": "Group 2: Glimepiride Alone", "description": "Glimepiride: Glimepiride tablets, 2 mg"}, {"id": "OG005", "title": "Group 2: Bexagliflozin + Glimepiride", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nGlimepiride: Glimepiride tablets, 2 mg"}, {"id": "OG006", "title": "Group 3: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG007", "title": "Group 3: Sitagliptin Alone", "description": "Sitagliptin: Sitagliptin tablets, 100 mg"}, {"id": "OG008", "title": "Group 3: Bexagliflozin + Sitagliptin", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nSitagliptin: Sitagliptin tablets, 100 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "17"}, {"groupId": "OG004", "value": "18"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "18"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "18"}]}], "classes": [{"title": "Bexagliflozin PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "17"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "18"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "1154.4", "spread": "35.1"}, {"groupId": "OG002", "value": "1008.6", "spread": "40.2"}, {"groupId": "OG003", "value": "1204.9", "spread": "48.6"}, {"groupId": "OG005", "value": "1162.2", "spread": "47.8"}, {"groupId": "OG006", "value": "1011.8", "spread": "21.5"}, {"groupId": "OG008", "value": "1158.1", "spread": "21.9"}]}]}, {"title": "Metformin PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG001", "value": "13351.9", "spread": "22.5"}, {"groupId": "OG002", "value": "13784.6", "spread": "26.0"}]}]}, {"title": "Glimepiride PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "18"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "0"}, {"groupId": "OG008", "value": "0"}]}], "categories": [{"measurements": [{"groupId": "OG004", "value": "496.1", "spread": "53.3"}, {"groupId": "OG005", "value": "633.0", "spread": "38.5"}]}]}, {"title": "Sitagliptin PK parameters", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "0"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG007", "value": "3579.6", "spread": "14.7"}, {"groupId": "OG008", "value": "3692.8", "spread": "16.9"}]}]}], "analyses": [{"groupIds": ["OG000", "OG002"], "groupDescription": "Geometric LS Mean was used as PK parameters", "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "The acceptance range for bioequivalence is 80.0 - 125.00%", "paramType": "Ratio of Geometric LSM", "paramValue": "87.36", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "80.02", "ciUpperLimit": "95.38", "estimateComment": "Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect"}, {"groupIds": ["OG001", "OG002"], "groupDescription": "Geometric LS Mean was used as PK parameters", "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "The acceptance range for bioequivalence is 80.0 - 125.00%", "paramType": "Ratio of Geometric LSM", "paramValue": "103.24", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "94.59", "ciUpperLimit": "112.68", "estimateComment": "Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect"}, {"groupIds": ["OG003", "OG005"], "groupDescription": "Geometric LS Mean was used as PK parameters", "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "The acceptance range for bioequivalence is 80.0 - 125.00%", "paramType": "Ratio of Geometric LSM", "paramValue": "94.46", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "80.34", "ciUpperLimit": "111.06", "estimateComment": "Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect"}, {"groupIds": ["OG004", "OG005"], "groupDescription": "Geometric LS Mean was used as PK parameters", "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "The acceptance range for bioequivalence is 80.0 - 125.00%.", "paramType": "[Ratio of Geometric LSM]", "paramValue": "127.19", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "110.33", "ciUpperLimit": "146.62", "estimateComment": "Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect"}, {"groupIds": ["OG006", "OG008"], "groupDescription": "Geometric LS Mean was used as PK parameters", "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "The acceptance range for bioequivalence is 80.0 - 125.00%", "paramType": "[Ratio of Geometric LSM]", "paramValue": "113.09", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "107.61", "ciUpperLimit": "118.86", "estimateComment": "Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect"}, {"groupIds": ["OG007", "OG008"], "groupDescription": "Geometric LS Mean was used as PK parameters", "nonInferiorityType": "EQUIVALENCE", "nonInferiorityComment": "The acceptance range for bioequivalence is 80.0 - 125.00%", "paramType": "[Ratio of Geometric LSM]", "paramValue": "103.16", "ciPctValue": "90", "ciNumSides": "TWO_SIDED", "ciLowerLimit": "99.30", "ciUpperLimit": "107.17", "otherAnalysisDescription": "Confidence interval from ANOVA with treatment, period, and sequence as fixed effects, and subject as a random effect"}]}, {"type": "SECONDARY", "title": "Urinary Glucose Excretion up to 0-72 hr", "description": "Pre-dose urine samples were collected from -12 to 0 h for baseline measurement. Subjects was instructed to empty their bladder prior to dosing. Post-dose urine was collected in 4 batches for Groups 1 and 2 at 0 to 12 h, 12 to 24 h, 24 o 36 h, and 36 to 48 h collections. Post-dose urine was collected in batches for Group 3 at 0 to 12 h, 12 to 24 h, 24 to 36 h, 36 to 48 h, 48 to 60 h and 60 to 72 h.", "populationDescription": "Only subjects with data in the specific category is analyzed", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Deviation", "unitOfMeasure": "g", "timeFrame": "up to 0-72 hr", "groups": [{"id": "OG000", "title": "Group 1: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG001", "title": "Group 1: Metformin Alone", "description": "Metformin: Metformin tablets, 1000 mg"}, {"id": "OG002", "title": "Group 1: Bexagliflozin + Metformin", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nMetformin: Metformin tablets, 1000 mg"}, {"id": "OG003", "title": "Group 2: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG004", "title": "Group 2: Glimepiride Alone", "description": "Glimepiride: Glimepiride tablets, 4 mg"}, {"id": "OG005", "title": "Group 2: Bexagliflozin + Glimepiride", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nGlimepiride: Glimepiride tablets, 4 mg"}, {"id": "OG006", "title": "Group 3: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg"}, {"id": "OG007", "title": "Group 3: Sitagliptin Alone", "description": "Sitagliptin: Sitagliptin tablets, 100 mg"}, {"id": "OG008", "title": "Group 3: Bexagliflozin + Sitagliptin", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nSitagliptin: Sitagliptin tablets, 100 mg"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "17"}, {"groupId": "OG004", "value": "17"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "18"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "18"}]}], "classes": [{"title": "0 - 12 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "17"}, {"groupId": "OG004", "value": "16"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "18"}, {"groupId": "OG007", "value": "12"}, {"groupId": "OG008", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "31.57", "spread": "8.06"}, {"groupId": "OG001", "value": "0.02", "spread": "0.01"}, {"groupId": "OG002", "value": "26.26", "spread": "8.86"}, {"groupId": "OG003", "value": "36.99", "spread": "14.24"}, {"groupId": "OG004", "value": "1.26", "spread": "4.37"}, {"groupId": "OG005", "value": "31.02", "spread": "11.19"}, {"groupId": "OG006", "value": "29.01", "spread": "6.84"}, {"groupId": "OG007", "value": "0.03", "spread": "0.01"}, {"groupId": "OG008", "value": "23.94", "spread": "7.17"}]}]}, {"title": "12 - 24 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "17"}, {"groupId": "OG004", "value": "17"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "18"}, {"groupId": "OG007", "value": "18"}, {"groupId": "OG008", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "17.32", "spread": "11.81"}, {"groupId": "OG001", "value": "0.04", "spread": "0.03"}, {"groupId": "OG002", "value": "22.57", "spread": "8.29"}, {"groupId": "OG003", "value": "26.85", "spread": "9.51"}, {"groupId": "OG004", "value": "0.04", "spread": "0.05"}, {"groupId": "OG005", "value": "22.59", "spread": "11.15"}, {"groupId": "OG006", "value": "24.38", "spread": "7.92"}, {"groupId": "OG007", "value": "0.04", "spread": "0.05"}, {"groupId": "OG008", "value": "22.85", "spread": "9.59"}]}]}, {"title": "24 - 36 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "16"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "17"}, {"groupId": "OG004", "value": "17"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "18"}, {"groupId": "OG007", "value": "15"}, {"groupId": "OG008", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "23.94", "spread": "9.16"}, {"groupId": "OG001", "value": "0.04", "spread": "0.04"}, {"groupId": "OG002", "value": "19.50", "spread": "8.94"}, {"groupId": "OG003", "value": "29.79", "spread": "10.24"}, {"groupId": "OG004", "value": "0.20", "spread": "0.42"}, {"groupId": "OG005", "value": "28.46", "spread": "11.37"}, {"groupId": "OG006", "value": "22.31", "spread": "8.97"}, {"groupId": "OG007", "value": "0.17", "spread": "0.56"}, {"groupId": "OG008", "value": "24.15", "spread": "9.27"}]}]}, {"title": "36 - 48 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "18"}, {"groupId": "OG001", "value": "18"}, {"groupId": "OG002", "value": "18"}, {"groupId": "OG003", "value": "17"}, {"groupId": "OG004", "value": "17"}, {"groupId": "OG005", "value": "18"}, {"groupId": "OG006", "value": "18"}, {"groupId": "OG007", "value": "17"}, {"groupId": "OG008", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG000", "value": "8.91", "spread": "4.97"}, {"groupId": "OG001", "value": "0.02", "spread": "0.01"}, {"groupId": "OG002", "value": "5.53", "spread": "4.17"}, {"groupId": "OG003", "value": "11.03", "spread": "7.84"}, {"groupId": "OG004", "value": "0.03", "spread": "0.01"}, {"groupId": "OG005", "value": "9.34", "spread": "7.55"}, {"groupId": "OG006", "value": "9.83", "spread": "6.67"}, {"groupId": "OG007", "value": "0.03", "spread": "0.01"}, {"groupId": "OG008", "value": "10.17", "spread": "5.23"}]}]}, {"title": "48 - 60 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "18"}, {"groupId": "OG007", "value": "15"}, {"groupId": "OG008", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG006", "value": "11.32", "spread": "8.09"}, {"groupId": "OG007", "value": "0.05", "spread": "0.07"}, {"groupId": "OG008", "value": "11.50", "spread": "7.52"}]}]}, {"title": "60 - 72 hours", "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "0"}, {"groupId": "OG001", "value": "0"}, {"groupId": "OG002", "value": "0"}, {"groupId": "OG003", "value": "0"}, {"groupId": "OG004", "value": "0"}, {"groupId": "OG005", "value": "0"}, {"groupId": "OG006", "value": "17"}, {"groupId": "OG007", "value": "17"}, {"groupId": "OG008", "value": "18"}]}], "categories": [{"measurements": [{"groupId": "OG006", "value": "2.67", "spread": "3.55"}, {"groupId": "OG007", "value": "0.02", "spread": "0.01"}, {"groupId": "OG008", "value": "2.70", "spread": "2.91"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "1", "timeFrame": "Adverse event collection began on the first clinical admission day (Day 0) and continued through D17. The subjects were actively monitored for serious adverse events for at least 14 days after discharge from the study.", "eventGroups": [{"id": "EG000", "title": "Group 1: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 3, "otherNumAtRisk": 18}, {"id": "EG001", "title": "Group 1: Metformin Alone", "description": "Metformin: Metformin tablets, 1000 mg", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 11, "otherNumAtRisk": 18}, {"id": "EG002", "title": "Group 1: Bexagliflozin + Metformin", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nMetformin: Metformin tablets, 1000 mg", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 13, "otherNumAtRisk": 18}, {"id": "EG003", "title": "Group 2: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 6, "otherNumAtRisk": 18}, {"id": "EG004", "title": "Group 2: Glimepiride Alone", "description": "Glimepiride: Glimepiride tablets, 2 mg", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 2, "otherNumAtRisk": 18}, {"id": "EG005", "title": "Group 2: Bexagliflozin + Glimepiride", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nGlimepiride: Glimepiride tablets, 2 mg", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 4, "otherNumAtRisk": 18}, {"id": "EG006", "title": "Group 3: Bexagliflozin Alone", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 3, "otherNumAtRisk": 18}, {"id": "EG007", "title": "Group 3: Sitagliptin Alone", "description": "Sitagliptin: Sitagliptin tablets, 100 mg", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 1, "otherNumAtRisk": 18}, {"id": "EG008", "title": "Group 3: Bexagliflozin + Sitagliptin", "description": "Bexagliflozin: Bexagliflozin tablets, 20 mg\n\nSitagliptin: Sitagliptin tablets, 100 mg", "deathsNumAffected": 0, "deathsNumAtRisk": 18, "seriousNumAffected": 0, "seriousNumAtRisk": 18, "otherNumAffected": 2, "otherNumAtRisk": 18}], "otherEvents": [{"term": "Diarrhea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 9, "numAffected": 9, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 7, "numAffected": 7, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Nausea", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 3, "numAffected": 3, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 3, "numAffected": 3, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Dyspepsia", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Abdominal pain", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Abdominal pain upper", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Vomiting", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Flatulence", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Tenderness", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Vessel puncture site haemorrhage", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Puncture site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Puncture site swelling", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Fatigue", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Xerosis", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Catheter site induration", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Catheter site pain", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Gun shot wound", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Hypoglycemia", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 2, "numAffected": 2, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 3, "numAffected": 3, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Arthralgia", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Headache", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 4, "numAffected": 4, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 4, "numAffected": 4, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Dizziness", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Paresthesia", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Dysmenorrhea", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}]}, {"term": "Dermatitis contact", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Ecchymosis", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Swelling of face", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}, {"term": "Urticaria", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 20.0", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG001", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG002", "numEvents": 1, "numAffected": 1, "numAtRisk": 18}, {"groupId": "EG003", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG004", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG005", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG006", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG007", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}, {"groupId": "EG008", "numEvents": 0, "numAffected": 0, "numAtRisk": 18}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictiveAgreement": false}, "pointOfContact": {"title": "Program Director", "organization": "Translational Medicine Group", "email": "yhalvorsen@ccib.mgh.harvard.edu", "phone": "617-726-4236"}}}, "documentSection": {"largeDocumentModule": {"largeDocs": [{"typeAbbrev": "Prot", "hasProtocol": true, "hasSap": false, "hasIcf": false, "label": "Study Protocol", "date": "2016-09-01", "uploadDate": "2020-02-12T14:15", "filename": "Prot_000.pdf", "size": 630511}, {"typeAbbrev": "SAP", "hasProtocol": false, "hasSap": true, "hasIcf": false, "label": "Statistical Analysis Plan", "date": "2017-04-07", "uploadDate": "2021-06-28T12:44", "filename": "SAP_001.pdf", "size": 1109234}]}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003924", "term": "Diabetes Mellitus, Type 2"}], "ancestors": [{"id": "D000003920", "term": "Diabetes Mellitus"}, {"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "relevance": "LOW"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "asFound": "Type 2 Diabetes Mellitus", "relevance": "HIGH"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000068900", "term": "Sitagliptin Phosphate"}, {"id": "C000057619", "term": "Glimepiride"}, {"id": "C000705992", "term": "Bexagliflozin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}, {"id": "D000000889", "term": "Anti-Arrhythmia Agents"}, {"id": "D000007166", "term": "Immunosuppressive Agents"}, {"id": "D000007155", "term": "Immunologic Factors"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M335", "name": "Sitagliptin Phosphate", "asFound": "Percutaneous", "relevance": "HIGH"}, {"id": "M252104", "name": "Glimepiride", "asFound": "Bioequivalence", "relevance": "HIGH"}, {"id": "M333513", "name": "Bexagliflozin", "asFound": "Post-operative care", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}, {"id": "M4213", "name": "Anti-Arrhythmia Agents", "relevance": "LOW"}, {"id": "M10212", "name": "Immunosuppressive Agents", "relevance": "LOW"}, {"id": "M10201", "name": "Immunologic Factors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "AnArAg", "name": "Anti-Arrhythmia Agents"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}